LABU stock price rose to $38.05 as short-covering and speculative buying returned. With the biotech index in an uptrend, chartists highlight $39.50 as the next upside target based on Fibonacci retracement levels. The Fed’s plan to slower the balance sheet tightening process and the release of downbeat jobs data (which triggered bets over sooner-than-expected rate cuts) dragged down bond yields last week. The U.S. economy added 175,000 jobs in April, well below Wall Street expectations of 240,000. Health care and social assistance led the way with a gain of 87,000 jobs. In North America, Pop Mart said revenue surged more than 550% between 2023 and 2024. What's more, sales in the region climbed about 900% in the first quarter of 2025 compared with the same period a year ago — far outpacing the comparable figure for global growth, according to a Goldman Sachs analysis. The LABU stock price has held steady around $37.50 amid subdued volumes. Sector watchers say that any high-profile biotech merger news could act as a catalyst, given historical correlation data.